Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Proteomics Products May Reach $1.7 Billion by 2006

By Biotechdaily staff writers
Posted on 20 May 2002
By 2006, total revenues of proteomics-related products are forecast to approach US$1.7 billion, according to a new report from Business Communications Co. More...
(Proteomics: An Assessment of Technology and Commercial Potential, BCI, Inc., Norwalk, CT, USA). Since revenues for selected proteomics products totaled $720 million in 2001, the 2006 forecast would represent an average annual growth rate (AAGR) of just over 18%. This growth is largely due to a boom in scientific discoveries stemming from the human genome project and from advances in high-throughput technologies for protein studies. Other contributing factors are increases in funding for research and an increased interest in drug discovery from pharmaceutical and biotechnology companies.

Today, researchers can analyze protein expression in an entire cell rather than studying individual proteins, notes the report. Newer techniques allow scientists to isolate proteins and identify them more quickly. The development of new technologies for studying proteins has led to a rapid growth in industries supplying instruments and reagents for proteomics studies. In turn, this had made a variety of products easily available from companies eager to compete in the new market.

The market for mass spectroscopy for proteomics represents more than 40% of the total market and is forecast to double in five years, from $300 million in 2001 to $603 million by 2006. The nascent market for protein chips and bioinformatics is expected to rise from $114 million in 2001 to $275 million in 2006. Two-dimensional electrophoresis will see lower growth (11%), while capillary electrophoresis will rise at an AAGR of over 15% during the period.

Factors influencing the growth of the market for drug delivery instruments and services include the continuing investments of national governments into technology-based companies and technology-based not-for-profit research, the push by big pharmaceutical companies to fill their blockbuster pipelines, and efforts by small biotechnology companies to become bigger companies. As all of these groups continue their efforts, says BCC, they will in turn drive the development of new instruments and new technologies.





Related Links:
BCC

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Electrolyte Analyzer
BKE-B
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.